|Dr. Hongbing Wang
Department of Pharmaceutical Sciences
20 Penn Street
Health Sciences Facility II Room 549
Baltimore, MD 21201
410-706-1280 – phone
410-706-5017 – fax
Pharmacokinetic-based drug-drug interactions and drug-induced liver toxicity are major concerns in both drug development and clinical practice. Alteration of hepatic drug-metabolizing enzymes and transporters represent the basis for many of these drug-drug interactions and hepatotoxicities. During the past decade, accumulating evidence has revealed that xenobiotic receptors, such as the pregnane X receptor (PXR), the constitutive androstane receptor (CAR), and the aryl hydrocarbon receptor (AhR), significantly contribute to the transcriptional regulation of many drug-metabolizing enzymes and transporters. Our laboratory is interested in studying both the regulation and function of drug-metabolizing/detoxifying enzymes and transporters in the human liver. Our specific research focus is centered on the molecular mechanisms of xenobiotic receptor-mediated transcriptional regulation of cytochrome P450s and uptake/efflux transporters in the human liver; the roles of specific P450s (e.g. CYP2B6 and CYP3A4) and/or transporters (e.g. BCRP and BSEP) on drug-induced liver toxicity; and the effects of gene-drug interactions on the expression of P450s in the human liver. Primary cultures of human hepatocytes and transgenic animals have been utilized as major models in the laboratory to predict metabolism-mediated drug-drug interactions and cytotoxicities, nuclear receptor-regulated enzyme expression, and species-specific enzyme induction. Our research projects include aspects of cellular biology, molecular biology, toxicology, and metabolism while utilizing a wide variety of techniques ranging from subcellular approaches to the use of entire animals.